Investors

About AVROBIO

AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose.

Stock Quote

Press Releases
August 28, 2018
AVROBIO, Inc. to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative lentiviral-based gene therapies to treat rare diseases following a single dose, today announced members of its

August 8, 2018
AVROBIO, Inc. to Present at the 2018 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative lentiviral-based gene therapies to treat rare diseases following a single dose, today announced that Geoff

Stock Chart

Copyright West LLC. Minimum 15 minutes delayed.